CVKD Cadrenal Therapeutics, Inc. Common Stock
Healthcare$5.19+0.00%ClosedMarket Cap: $14.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
6.95
P/S
0.00
EV/EBITDA
-1.05
DCF Value
$1.72
FCF Yield
-73.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-411.0%
ROA
-415.4%
ROIC
-670.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-2.5M | $-2.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.1M | $-3.0M | $— | — |
| FY null | $0.00 | NaN% | $-13.5M | $-13.2M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-2.7M | $-2.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.7M | $-3.7M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-3.9M | $-3.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.3M | $-4.2M | $— | — |
| FY null | $0.00 | NaN% | $-11.0M | $-10.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.5M | $-2.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.5M | $-2.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.8M | $-1.7M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-1.3M | $-1.1M | $-1.32 | — |